Current advances in Hodgkin's lymphoma. Issue 1 (March 2019)

• Record Type: Journal Article
• Authors: Vadakara, Joseph; Andrick, Benjamin
• Is Part Of: Chronic diseases and translational medicine. Volume 5:Issue 1(2019)
• Page Start: 15
• Page End: 24
• Publication Date: 2019-03
• Subjects: Hodgkin's lymphoma -- Brentuximab vedotin -- Nivolumab -- Pembrolizumab -- Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); Chronic diseases -- Periodicals; Medicine -- Research -- Periodicals; Chronic diseases; Medicine -- Research; Chronic Disease; Translational Medical Research; Periodicals; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.044
• DOI: 10.1016/j.cdtm.2019.02.003
• Languages: English
• ISSNs: 2095-882X

Abstract

Abstract: Hodgkin's lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin's lymphoma. This is a review of the current advances in the management of Hodgkin's lymphoma and a review of ongoing clinical trials in the field.